Developing therapeutic monoclonal antibodies at pandemic pace

The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months.

Detalles Bibliográficos
Autor principal: Kelley, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173776/
https://www.ncbi.nlm.nih.gov/pubmed/32317764
http://dx.doi.org/10.1038/s41587-020-0512-5
_version_ 1783524508563406848
author Kelley, Brian
author_facet Kelley, Brian
author_sort Kelley, Brian
collection PubMed
description The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months.
format Online
Article
Text
id pubmed-7173776
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-71737762020-04-22 Developing therapeutic monoclonal antibodies at pandemic pace Kelley, Brian Nat Biotechnol Comment The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months. Nature Publishing Group US 2020-04-21 2020 /pmc/articles/PMC7173776/ /pubmed/32317764 http://dx.doi.org/10.1038/s41587-020-0512-5 Text en © Springer Nature America, Inc. 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
Kelley, Brian
Developing therapeutic monoclonal antibodies at pandemic pace
title Developing therapeutic monoclonal antibodies at pandemic pace
title_full Developing therapeutic monoclonal antibodies at pandemic pace
title_fullStr Developing therapeutic monoclonal antibodies at pandemic pace
title_full_unstemmed Developing therapeutic monoclonal antibodies at pandemic pace
title_short Developing therapeutic monoclonal antibodies at pandemic pace
title_sort developing therapeutic monoclonal antibodies at pandemic pace
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173776/
https://www.ncbi.nlm.nih.gov/pubmed/32317764
http://dx.doi.org/10.1038/s41587-020-0512-5
work_keys_str_mv AT kelleybrian developingtherapeuticmonoclonalantibodiesatpandemicpace

Ejemplares similares